Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Restoring antibacterial efficacy

New hydrogel helps overcome antibiotic resistance

In the laboratory, researchers increased the bactericidal effect of antibiotics 64-fold with the use of a new hydrogel. The material made the antibiotics effective even against resistant bacteria.

News • Incidentaloma detection

Liquid biopsy as diagnostic tool for pancreatic lesions

New research highlights the potential of liquid biopsy in diagnosing pancreatic incidentaloma - lesions which can occasionally signal pancreatic cancer in its earliest stages.

News • Blood vessel-like coating

New material to protect devices against blood clot formation

Protection against blood clots: A new material, designed to mimic blood vessels, could allow for safer use of devices like catheters, stents, blood-oxygenation machines and dialysis machines.